Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPark Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) trades at $2.41 with MoonshotScore 17/100 (Grade F). Sector: Consumer cyclical.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BYAH: BYAH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BYAH against Consumer Cyclical peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BYAH: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Strongest side: Valuation (5/10, Neutral). Weakest side: Momentum (0/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) Consumer Business Overview
Park Ha Biological Technology Co., Ltd. is a China-based investment holding company specializing in the development and distribution of skincare products under the “Park Ha” brand. The company operates in the competitive personal care market, utilizing direct sales and franchise models within the People's Republic of China.
What Is the Investment Thesis for BYAH?
Park Ha Biological Technology Co., Ltd. operates in the attractive Chinese skincare market, evidenced by a high gross margin of 90.6%. However, the company's negative profit margin of -965.0% raises concerns about operational efficiency and cost management. With a market capitalization of $0.00B and a negative P/E ratio of -0.03, the company's valuation is challenging. Growth catalysts include expanding its franchise network and enhancing its direct sales capabilities. Key risks include intense competition in the skincare market and the company's current lack of profitability. Monitoring the company's ability to improve its bottom line and effectively manage its operational costs is crucial for assessing its long-term viability.
Based on FMP financials and quantitative analysis
BYAH Key Highlights
Gross Margin of 90.6% indicates strong pricing power and efficient cost of goods sold.
- Negative Profit Margin of -965.0% signals significant operational inefficiencies or high operating expenses.
- Market Cap of $0.00B reflects the company's small size and potential illiquidity.
- P/E Ratio of -0.03 indicates the company is currently not profitable.
- Beta of -3.94 suggests the stock is significantly less volatile than the market, but may also reflect a lack of trading activity.
Who Are BYAH's Competitors?
BYAH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AZI Autozi Internet Technology (Global) Ltd. | $1.22 | -1.61% | $5.48M | — |
| BTBD BT Brands, Inc. | $1.77 | -1.12% | $11.0M | 395-pillar |
| CGTL Creative Global Technology Holdings Limited | $4.03 | -0.74% | $6.33M | 335-pillar |
| DSS DSS, Inc. | $0.75 | -3.29% | $7.54M | — |
| ROL Rollins, Inc. | $34.56 | +0.06% | $16.6B | 765-pillar |
| SCI Service Corporation International | $79.73 | +0.05% | $10.9B | 505-pillar |
| HRB H&R Block, Inc. | $44.89 | +0.02% | $5.69B | 955-pillar |
| FTDR Frontdoor, Inc. | $79.56 | -1.07% | $5.59B | 905-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BYAH's Key Strengths?
Established brand presence in the Chinese skincare market.
- Franchise network provides a scalable distribution model.
- High gross margin indicates strong pricing power.
- Focus on a specific niche within the consumer cyclical sector.
What Are BYAH's Weaknesses?
Negative profit margin indicates operational inefficiencies.
- Small market capitalization limits access to capital.
- Limited geographic diversification, relying solely on the Chinese market.
- High beta suggests potential volatility.
What Could Drive BYAH Stock Higher?
BYAH catalyst: Expansion of the franchise network into new regions within China, targeting Tier 2 and Tier 3 cities by Q4 2026.
- Development and launch of new skincare products catering to specific consumer needs and preferences, with a focus on natural and organic ingredients.
- Implementation of targeted marketing campaigns and social media strategies to enhance brand awareness and drive customer acquisition.
What Are the Key Risks for BYAH?
Financial-distress signal — its Altman Z-Score of -6.52 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established domestic and international brands, potentially impacting market share and profitability.
- Changes in consumer preferences and trends in the skincare market, requiring continuous innovation and adaptation.
- Regulatory changes and compliance requirements in China, potentially increasing operational costs and complexity.
- Economic downturns affecting consumer spending on discretionary items, potentially reducing demand for skincare products.
What Are the Growth Opportunities for BYAH?
- Expanding Franchise Network: Park Ha can grow by expanding its franchise network across China, particularly in Tier 2 and Tier 3 cities where demand for skincare products is increasing. The market size for skincare products in these regions is estimated to reach $50 billion by 2028. By offering attractive franchise terms and providing comprehensive support to franchisees, Park Ha can accelerate its market penetration and increase brand visibility. This expansion can be achieved within the next 3-5 years.
- Enhancing Direct Sales Capabilities: Investing in its direct sales channels, including online platforms and direct marketing initiatives, can enable Park Ha to reach a broader customer base and improve customer engagement. The e-commerce market for skincare products in China is projected to grow to $80 billion by 2027. By leveraging data analytics and personalized marketing, Park Ha can optimize its direct sales efforts and drive revenue growth. This initiative can be implemented within the next 2 years.
- Product Innovation and Diversification: Developing new and innovative skincare products that cater to specific consumer needs and preferences can help Park Ha differentiate itself from competitors and capture a larger market share. The demand for specialized skincare products, such as anti-aging and acne treatment solutions, is growing rapidly. By investing in research and development and collaborating with leading dermatologists, Park Ha can launch new products that address unmet consumer needs. This can be an ongoing effort with new products released every 12-18 months.
- Strengthening Brand Awareness: Implementing targeted marketing campaigns and leveraging social media platforms to enhance brand awareness and build brand loyalty can drive customer acquisition and retention. The use of Key Opinion Leaders (KOLs) and influencers in the beauty industry is highly effective in China. By partnering with popular KOLs and creating engaging content, Park Ha can increase its brand visibility and attract new customers. This is an ongoing opportunity with continuous marketing efforts.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with complementary businesses, such as beauty salons and spas, can expand Park Ha's distribution channels and reach new customer segments. Collaborating with these businesses can provide Park Ha with access to a wider customer base and enhance its brand image. This initiative can be pursued within the next 1-3 years, focusing on building mutually beneficial relationships.
What Are BYAH's Competitive Advantages?
- Brand Recognition: The “Park Ha” brand may have some level of recognition within the Chinese market, providing a competitive edge.
- Franchise Network: The established franchise network provides a distribution advantage and recurring revenue stream.
- Proprietary Formulations: The company's skincare products may contain unique formulations that differentiate them from competitors.
What Does BYAH Do?
Park Ha Biological Technology Co., Ltd. is an investment holding company that operates in the consumer cyclical sector, specifically within the personal products and services industry. The company focuses on the development, distribution, and sales of skincare products under its proprietary “Park Ha” brand. Headquartered in Wuxi, China, Park Ha conducts its business through subsidiaries that engage in direct product sales and franchise operations. The company's business model emphasizes a direct-to-consumer approach, leveraging franchise networks to expand its market reach across the People's Republic of China. Park Ha aims to cater to the growing demand for skincare products in the Chinese market by offering a range of products designed to meet diverse consumer needs. While the company's history and specific founding details are not provided, its current strategy revolves around strengthening its brand presence and optimizing its distribution channels to enhance profitability and market share in the competitive skincare industry. The company currently employs 31 individuals.
What Products and Services Does BYAH Offer?
- Develops skincare products under the “Park Ha” brand.
- Operates as an investment holding company.
- Engages in direct product sales through its subsidiaries.
- Provides franchise services to expand its distribution network.
- Focuses on the Chinese skincare market.
- Manages a portfolio of skincare products targeting various consumer needs.
How Does BYAH Make Money?
- Develops and markets skincare products under its own brand.
- Generates revenue through direct sales of products to consumers.
- Expands market reach through a franchise model, earning fees and royalties from franchisees.
What Industry Does BYAH Operate In?
The personal products and services industry is characterized by intense competition, evolving consumer preferences, and a constant need for innovation. The Chinese skincare market, in particular, is experiencing substantial growth, driven by increasing disposable incomes and a rising awareness of skincare products. Park Ha Biological Technology Co., Ltd. operates in this dynamic environment, competing with both domestic and international brands. Key trends include the growing popularity of e-commerce, the demand for natural and organic products, and the increasing influence of social media marketing. Companies like AZI, BTBD, CENN, CGTL, and DSS represent some of the competitors in this space, each vying for market share through different product offerings and distribution strategies.
Who Are BYAH's Key Customers?
- Consumers in the People's Republic of China seeking skincare products.
- Franchisees who operate Park Ha branded stores and sell products.
- Customers seeking a range of skincare solutions for different skin types and concerns.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 94% of our measures
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Why 17?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.55 Gross margin (Business Quality)
- +0.54 Price to book (Valuation)
- +0.47 Enterprise value vs sales (Valuation)
What is holding it back
- -0.78 Return on invested capital (Business Quality)
- -0.78 Return on equity (Business Quality)
- -0.78 Return on assets (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 50 |
| 2026-08-26 | 50 |
| 2026-08-29 | 50 |
| 2026-09-01 | 17 |
| 2026-09-04 | 17 |
| 2026-09-07 | 17 |
| 2026-09-10 | 17 |
What changed?
The grade moved from 50 to 17 (-33).
Over the same 18 days the stock moved -24.3%.
Company Profile
Park Ha Biological Technology Co., Ltd. Ordinary Shares operates in the Household & Personal Products industry within the Consumer Defensive sector. It is headquartered in Wuxi, CN. The company is led by CEO Xiaoqiu Zhang. BYAH has traded publicly since 2024.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) Valuation Context
Relative to its peer group, BYAH's quantitative score of 17/100 is below the peer average of 64/100.
Key Financial Metrics
Its free cash flow yield is -0.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.92 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Park Ha Biological Technology Co., Ltd. Ordinary Shares's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.52 places it in the distress zone, a signal of elevated financial risk.
BYAH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established brand presence in the Chinese skincare market.
- Franchise network provides a scalable distribution model.
- High gross margin indicates strong pricing power.
- Focus on a specific niche within the consumer cyclical sector.
Bear Case
- Negative profit margin indicates operational inefficiencies.
- Small market capitalization limits access to capital.
- Limited geographic diversification, relying solely on the Chinese market.
- High beta suggests potential volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
BYAH Latest News
-
12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
benzinga · Sep 11, 2026
-
BYAH Shareholder Alert: Park Ha Biological Technology Co., Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
prnewswire.com · Sep 10, 2026
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines – BYAH
globenewswire.com · Sep 8, 2026
-
SueWallSt Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - BYAH
globenewswire.com · Sep 8, 2026
BYAH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BYAH.
Price Targets
Wall Street price target analysis for BYAH.
BYAH MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. BYAH scores 17/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
BYAH Shareholder Alert: Park Ha Biological Technology Co., Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines – BYAH
SueWallSt Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - BYAH
Latest Park Ha Biological Technology Co., Ltd. Ordinary Shares Analysis
Leadership: Xiaoqiu Zhang
CEO
Xiaoqiu Zhang serves as the CEO of Park Ha Biological Technology Co., Ltd., overseeing the company's operations and strategic direction. Zhang is responsible for managing the company's 31 employees and ensuring the effective execution of its business strategy.
Track Record: As CEO, Xiaoqiu Zhang is responsible for guiding Park Ha Biological Technology Co., Ltd. through the challenges and opportunities of the Chinese skincare market. Specific achievements and milestones under Zhang's leadership are not detailed in the provided information. However, their focus is likely on expanding the company's franchise network, enhancing its direct sales capabilities, and improving its overall financial performance.
Common Questions About BYAH (Consumer Cyclical)
What does the AI Score mean for BYAH?
BYAH holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BYAH a good stock?
Stock Expert AI does not rate BYAH buy, sell or hold. Park Ha Biological Technology Co., Ltd. Ordinary Shares carries a MoonshotScore of 17/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BYAH stock?
As of March 17, 2026, there is no available analyst coverage or consensus rating for Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH).
What are the main risks for BYAH?
The main risks for Park Ha Biological Technology Co., Ltd. include intense competition in the Chinese skincare market, which is dominated by both domestic and international brands.
What are the key factors to evaluate for BYAH?
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) holds a MoonshotScore of 17/100 (low). Park Ha Biological Technology Co., Ltd. operates in the attractive Chinese skincare market, evidenced by a high gross margin of 90.6%. Not financial advice.
How frequently does BYAH data refresh on this page?
BYAH's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BYAH's recent stock price performance?
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand presence in the Chinese skincare market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BYAH overvalued or undervalued right now?
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BYAH?
Yes, most major brokerages offer fractional shares of Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, and the absence of analyst coverage introduces uncertainty.
- The company's future performance is subject to various risks and uncertainties, including competition, regulatory changes, and economic conditions.